The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?
Open accessAbstract
Purpose: Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT). Patients and Methods: We assessed changes in the incidence of TRM and overall survival from 1985 through 2004 in 5,972 patients younger than age 50 years who received myeloablative conditioning and HCT for acute myeloid leukemia (AML) in first complete remission (CR1) or second complete remission (CR2). Results: Among HLA-matched sibling donor transplantation recipients, the relative risks (RRs) for TRM were 0.5 and 0.3 for 2000 to 2004 compared with those for 1985 to 1989 in patients in CR1 and CR2, respectively (P < .001). The RRs for all causes of mortality in the latter period were 0.73 (P = .001) and 0.60 (P = .005) for the CR1 and CR2 groups, respectively. Among unrelated donor transplantation recipients, the RRs for TRM were 0.73 (P = .095) and 0.58 (P < .001) for 2000 to 2004 compared with those in 1990 to 1994 in the CR1 and CR2 groups, respectively. Reductions in mortality were observed in the CR2 group (RR, 0.74; P = .03) but not in the CR1 group. Conclusion: Our results suggest that innovations in transplantation care since the 1980s and 1990s have reduced the risk of TRM in patients undergoing allogeneic HCT for AML and that this reduction has been accompanied by improvements in overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Cited by
Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Råcil, Z., Rowe, J. M., Russell, N., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 400
McDonald, G. B., Sandmaier, B. M., Mielcarek, M., Sorror, M., Pergam, S. A., Cheng, G.-S., Hingorani, S., Boeckh, M., Flowers, M. D., Lee, S. J., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-2936 · Cited by 285
Prevalence of Hematopoietic Cell Transplant Survivors in the United States
Majhail, N. S., Tao, L., Bredeson, C., Davies, S., Dehn, J., Gajewski, J. L., Hahn, T., Jakubowski, A., Joffe, S., Lazarus, H. M., et al. (2013) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2013.07.020 · Cited by 258
Self-citation
Metadata
- Authors
- Horan, J. T., Logan, B. R., Agovi-Johnson, M.-A., Lazarus, H. M., Bacigalupo, A. A., Ballen, K. K., Bredeson, C. N., Carabasi, M. H., Gupta, V., Hale, G. A., Khoury, H. J., Juckett, M. B., Litzow, M. R., Martino, R., McCarthy, P. L., Smith, F. O., Rizzo, J. D., & Pasquini, M. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-01
- Volume
- 29
- Issue
- 7
- Pages
- 805-813
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128428511
- Cited by
- 203
- References
- 1
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? https://app.cochat.ai/papers/10.1200/jco.2010.32.5001
- The paper
- Horan, J. T., Logan, B. R., Agovi-Johnson, M.-A., Lazarus, H. M., Bacigalupo, A. A., Ballen, K. K., Bredeson, C. N., Carabasi, M. H., Gupta, V., Hale, G. A., Khoury, H. J., Juckett, M. B., Litzow, M. R., Martino, R., McCarthy, P. L., Smith, F. O., Rizzo, J. D., & Pasquini, M. C. (2011). Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.32.5001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.